WHAT NEXT FOR OVOCA BIO INVESTORS? July 25, 2024 IN A surprise move after the failure of the clinical trials for Ovoca Bio’s Orenetide drug, the CEO, Kirill Golovanov, resigned last week.... Read more »
ANNUAL 2023: MONEYBAGS – WINNERS AND LOSERS IN 2023 November 15, 2023 THESE ARE pretty uncertain times courtesy of the wars in Ukraine and Gaza, inflation, and interest rates. Different sectors have dealt with the... Read more »
WAITING ON OVOCA BIO’S BLOCKBUSTER DRUG August 10, 2023 AS AN Irish company now dominated by Russian shareholders, Ovoca Bio has been badly impacted by the Ukraine war and CEO Kirill Golovanov... Read more »
